Myxoid Liposarcoma clinical trials

Explore recruiting myxoid liposarcoma clinical trials.

Recruiting myxoid liposarcoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Myxoid Liposarcoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR™ T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (SPEARHEAD 1 STUDY)

France, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors (IGNYTE-ESO)

Spain, Netherlands, France, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

EPITOME-1015-I: A phase I study to investigate the safety and tolerability of MDG1015 in patients with epithelial ovarian cancer, gastroesophageal adenocarcinoma, round cell liposarcoma and/or synovial sarcoma

Netherlands

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies

Netherlands, Spain, Italy

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With US Standard of Care in Adult Participants With Locally Recurrent, InoperaBLE, or Metastatic Soft Tissue Sarcomas - (THE INVINCIBLE-3 TRIAL)

Spain, France, Poland, Germany, Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

Phase I/II randomized trial of LB-100 plus doxorubicin vs. doxorubicin alone in first line of advanced soft tissue sarcomas

Spain

Phase I and Phase II (Integrated)- Bioequivalence Study EU CTIS Study details

Myxoid Liposarcoma trials by city

Myxoid Liposarcoma in Toronto Myxoid Liposarcoma in Vancouver Myxoid Liposarcoma in Montreal Myxoid Liposarcoma in Calgary Myxoid Liposarcoma in Edmonton Myxoid Liposarcoma in Ottawa Myxoid Liposarcoma in Winnipeg Myxoid Liposarcoma in Quebec City Myxoid Liposarcoma in Hamilton Myxoid Liposarcoma in Kitchener Myxoid Liposarcoma in London Myxoid Liposarcoma in Halifax Myxoid Liposarcoma in New York Myxoid Liposarcoma in Los Angeles Myxoid Liposarcoma in Chicago Myxoid Liposarcoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease